Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden.

Blood cancer journal - 12 Oct 2020

Wang Yu-Hung, Lin Chien-Chin, Lee Sze-Hwei, Tsai Xavier Cheng-Hong, Wu Shan-Ju, Hou Hsin-An, Huang Tai-Chung, Kuo Yuan-Yeh, Yao Ming, Chang Koping, Lin Chung-Wu, Lin Yun-Chu, Tien Fen-Ming, Chou Wen-Chien, Tang Jih-Luh, Tien Hwei-Fang

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Amino Acid Substitution
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Mutation, Missense

Share to Primary Myelofibrosis

Share to Repressor Proteins

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 33046688
DOI: 10.1038/s41408-020-00364-5
PMCID: PMC7550588

Genes

ASXL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden.PMID 33046688Read ↗

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera.Semantic proximity Read ↗

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.Semantic proximity Read ↗

ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival.Semantic proximity Read ↗

Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.Semantic proximity Read ↗

Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia.Semantic proximity Read ↗

U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotypeSemantic proximity Read ↗

Highly variable mutational profile of ASXL1 in myelofibrosis.Semantic proximity Read ↗

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study GroupSemantic proximity Read ↗

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.Semantic proximity Read ↗

ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia.Semantic proximity Read ↗

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.Semantic proximity Read ↗

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.